Twice-Daily Trizivir versus Combivir-Abacavir in Antiretroviral-Experienced Adults with Human Immunodeficiency Virus-1 Infection: A Formulation-Switch Trial

Pharmacotherapy

Volumn 23, Issue 11, 2003, Pages 1432-1440

  Fischl, Margaret A ^a   Burnside Jr , Alfred F ^b   Farthing, Charles F ^c   Thompson, Melanie A ^d   Bellos, Nicholaos C ^e   Williams, Vanessa C ^f   Kauf, Teresa L ^f   Wannamaker, Paul G ^f   Shaefer, Mark S ^f  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b Burnside Clinic   (United States)

^c AIDS HEALTHCARE FOUNDATION   (United States)

^d AIDS Research Consortium of Atlanta   (United States)

^e Southwest Infectious Disease Associates   (United States)

^f GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; VIRUS RNA; ZIDOVUDINE;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ANOREXIA; ARTICLE; BLOOD; BRONCHITIS; CHEMISTRY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HERNIA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; INTESTINE OBSTRUCTION; MAJOR CLINICAL STUDY; MALE; METABOLISM; MULTICENTER STUDY; NAUSEA; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STILLBIRTH; URINARY TRACT INFECTION; VOMITING;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ANTI-HIV AGENTS; CHEMISTRY, PHARMACEUTICAL; CONFIDENCE INTERVALS; DIDEOXYNUCLEOSIDES; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; RNA, VIRAL; ZIDOVUDINE;

EID: 0142213718     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.23.14.1432.31944     Document Type: Article

References (32)

1. Carpenter CCJ, Cooper DA, Fischl MA, et al. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA panel. JAMA 2000;283:381-90.
2. Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Available from http://www.hivatis.org/ trtgdlns.html. Accessed February 19, 2003.
3. Fogarty L, Roter D, Larson S, Burke J, Gillespie J, Levy R. Patient adherence to HIV medication regimens: a review of published and abstract reports. Patient Educ Counsel 2002;46:93-108.
4. Staszewski S, Keiser P, Montaner J, et al. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naïve HIV-infected adults: a randomized equivalence trial. JAMA 2001;285:1155-63.
5. Matheron S, Descamps D, Boué F, et al. Triple nucleoside combination zidovudine/lamivudine/abacavir versus zidovudine/lamivudine/nelfinavir as first-line therapy in HIV-1-infected adults: a randomized trial. Antivir Ther 2003;8:163-71.
6. Vibhagool A, on behalf of the CNA3014 International Study Team. Abacavir/Combivir (ABC/COM) is comparable to indinavir/Combivir (IDV/COM) in HIV-1-infected antiretroviral therapy naive adults: results of a 48-week open-label study (CNA3014). Presented as a poster at the 1st IAS conference on HIV pathogenesis and treatment, Buenos Aires, Argentina, July 8-11, 2001.
7. Henry K, Wallace RJ, Bellman PC, et al. Twice-daily triple nucleoside intensification treatment with lamivudine-zidovudine plus abacavir sustains suppression of human immunodeficiency virus t),pe 1: results of the TARGET study. J Infect Dis 2001;183:571-8.
8. Yuen GJ, Lou Y, Thompson NF, et al. Abacavir/lamivudine/ zidovudine as a combined formulation tablet: bioequivalence compared with each component administered concurrently and the effect of food on absorption. J Clin Pharmacol 2001;41:277-88.
9. Cremieux AC, Katlama C, Gillotin C, Demarles D, Yuen GJ, Raffi F. A comparison of the steady-state pharmacokinetics and safety of abacavir, lamivudine, and zidovudine taken as a triple combination tablet and as abacavir plus a lamivudine-zidovudine double combination tablet by HIV-1-infected adults. Pharmacotherapy 2001;21:424-30.
10. Katlama C, Fenske S, Gazzard B, et al. TRIZAL study: switching from successful HAART to Trizivir (abacavir-lamivudine-zidovudine combination tablet): 48 weeks efficacy, safety and adherence results. HIV Med 2003;4:79-86.
11. Childress JK, Jhingran P, Scott-Lennox J, Tolson J. Development and initial evaluation of the patient medication adherence questionnaire (PMAQ). Presented at the 6th European conference on clinical aspects and treatment of HIV infection, Hamburg, Germany, October 11-15, 1997.
12. DeMasi RA, Graham NM, Tolson JM, et al. Correlation between self-reported adherence to highly active antiretroviral therapy (HAART) and virologic outcome. Adv Ther 2001;18:167-73.
13. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep 1992;41(RR-17):1-19.
14. Food and Drug Administration. E9 statistical principles for clinical trials. Federal Register 1998;63:49583-98.
15. Committee for Proprietary Medicinal Products European Working Party. Points to consider on biostatistical/ methodological issues arising from recent CPMP discussions on licensing applications: superiority, non-inferiority and equivalence. London: CPMP European Working Party, 1999.
16. Ruane PJ, Parenti DM, Margolis DM, et al. Compact quadruple antiretroviral therapy with the lamivudine/ zidovudine combination tablet plus abacavir/efavirenz and the lamivudine/zidovudine/abacavir triple nucleoside tablet plus efavirenz in treatment-naive HIV-infected adults. HIV Clin Trials 2003;4:231-43.
17. Eron JJ Jr, Yetzer ES, Ruane PJ, et al. Efficacy, safety, and adherence with a twice-daily combination lamivudine/ zidovudine tablet formulation, plus a protease inhibitor, in HIV infection. AIDS 2000;14:671-81.
18. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000;133:21-30.
19. Gordillo V, del Amo J, Soriano V, et al. Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. AIDS 1999;13:1763-9.
20. Bangsberg DR, Hecht FM, Charlebois ED, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS 2000;14:357-66.
21. Eldred LJ, Wu AW, Chaisson RE, et al. Adherence to antiretroviral and pneumocystis prophylaxis in HIV disease. J Acquir Immune Defic Syndr 1998;18:117-25.
22. Wenger N, Gifford A, Liu H, et al. Patient characteristics and attitudes associated with antiretroviral (AR) adherence. Presented at the 6th conference on retroviruses and opportunistic infections, Chicago, IL, January 31-February 4, 1999.
23. Jordan J, Carranza Rosenzweig J, Pathak D, Pilon T. Perceived influence of regimen characteristics on adherence. Presented as a poster at the 5th international congress on drug therapy in HIV infection, Glasgow, Scotland, October 22-26, 2000.
24. Mannheimer S, Friedland G, Matts J, et al. The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clin Infect Dis 2002;34:1115-21.
25. Low-Beer S, Yip B, O'Shaughnessy MV, Hogg RS, Montaner JSG. Adherence to triple therapy and viral load response. J AIDS 2000;23:360-1.
26. Opravil M, Hirschel B, Lazzarin A, et al. A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection. J Infect Dis 2002;185:1251-60.
27. Gifford AL, Cunningham WE, Heslin KC, et al. Participation in research and access to experimental treatments by HIV-infected patients. N Engl J Med 2002;346:1373-82.
28. Centers for Disease Control and Prevention. HIV/AIDS surveillance report 2001;13(2):1-44. Available from http://www.cdc.gov/hiv/stats/hasrlink.htm.
29. Singh N, Squier C, Sivek C, Wagener M, Nguyen MH, Yu VL. Determinants of compliance with antiretroviral therapy in patients with human immunodeficiency virus - prospective assessment with implications for enhancing compliance. AIDS Care 1996;8:261-9.
30. Clumeck N, Goebel F, Rozenbaum W, et al. Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA. AIDS 2001;15:1517-26.
31. Walli R, Michl GM, Bogner JR, Goebel FD. Improvement of HAART-associated insulin resistance and dyslipidemia after replacement of protease inhibitors with abacavir. Eur J Med Res 2001;6:413-21.
32. Hetherington S, McGuirk S, Powell G, et al. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Ther 2001;23:1603-14.